60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 51,400 shares, an increase of 252.1% from the February 28th total of 14,600 shares. Based on an average daily trading volume, of 437,500 shares, the short-interest ratio is presently 0.1 days. Approximately 3.7% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several research analysts have commented on SXTP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Saturday, March 22nd. HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday.

60 Degrees Pharmaceuticals Stock Up 1.4 %

Shares of 60 Degrees Pharmaceuticals stock opened at $1.85 on Friday. 60 Degrees Pharmaceuticals has a 12 month low of $1.41 and a 12 month high of $35.99. The stock has a market cap of $2.72 million, a PE ratio of -0.18 and a beta of 4.52. The business has a fifty day simple moving average of $2.65 and a 200-day simple moving average of $4.67.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.